ARCHIVES

Ibrutinib Demonstrates 71% ORR In Phase Ib/II CLL and SLL Study

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

Recalcitrant Cancer Bill Heading To Senate May Face Hold in the Lame Duck Session

November 16, 2012

DCPC Concepts OKd Include Nurse Research Training

May 25, 1984

FDA’s Handling Of UFT Raises Questions About Agency’s Isolation, Grasp Of Science.

July 21, 2000

Masons Give $65 Million to Univ. of Minnesota Cancer Center.

April 25, 2008

NCI-Approved Clinical Trials

November 26, 2004

Karmanos Cancer Center Wins $4.6M From U.S. Army.

September 5, 2008